The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BB Biotech AG's current ratio for the quarter that ended in Dec. 2023 was 0.31.
BB Biotech AG has a current ratio of 0.31. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If BB Biotech AG has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for BB Biotech AG's Current Ratio or its related term are showing as below:
LSE:0JYO's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.79 * Ranked among companies with meaningful Current Ratio only.
BB Biotech AG Current Ratio Historical Data
The historical data trend for BB Biotech AG's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BB Biotech AG's Current Ratio
For the Biotechnology subindustry, BB Biotech AG's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BB Biotech AG's Current Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BB Biotech AG's Current Ratio distribution charts can be found below:
* The bar in red indicates where BB Biotech AG's Current Ratio falls into.
BB Biotech AG Current Ratio Calculation
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
BB Biotech AG's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BB Biotech AG (LSE:0JYO) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
BB Biotech AG Current Ratio Related Terms
Thank you for viewing the detailed overview of BB Biotech AG's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:0JYO has been successfully added to your 